Skip to content
Screener

Exelixis EXEL Q3 2026 earnings

Reported October 29, 2026 · After market close

Revenue$658.7MBeat by $12.2M
EPS$0.94Beat by $0.05
Revenue estimate$646.5M
EPS estimate$0.89
“The zanzalintinib development program gained further momentum as the organization focused on trial initiations, enrollment progress for ongoing studies and in-depth planning for the next wave of new pivotal trials. The enthusiasm around the zanzalintinib franchise continues, and we look forward to sharing more progress when appropriate. As we execute on our priorities, we remain disciplined in our deployment of capital as we invest in our R&D portfolio, return value to shareholders through our stock repurchase program and actively evaluate external innovation opportunities that can strengthen our pipeline and create long-term value for patients and all of our stakeholders.”
Michael M. Morrissey

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$658.7M+10.2%
Gross profit$632.5M+9.2%
Operating income$268.4M+13.5%
Net income$218.1M+12.7%
EPS (diluted)$0.85+23.2%

Balance sheet

See full
Cash & equivalents$304.8M-19.0%
Total debt$162.2M-8.1%
Total equity$1.8B-15.1%
Total assets$2.5B-11.0%

Cash flow

See full
Operating cash flow$280.0M-3.6%
CapEx$2.5M+67.9%
Free cash flow$277.5M-3.9%

Valuation & ratios

Valuation

as of 10/30/26
See full
Market cap$16.4B+56.5%
Enterprise value$16.26B+54.9%
P/E18.5×+1.1×
P/S6.6×+1.9×

Profitability

See full
Gross margin96.3%-0.4pp
Operating margin40.2%+5.2pp
Net margin35.5%+5.8pp
FCF margin46.5%+12.4pp

Returns & leverage

See full
Return on equity44.3%+13.8pp
Debt / equity0.1×0.0×
Current ratio3.2×-0.5×

Segments

By product

See full
Gross product revenues$853.7M+9.4%
License revenues$58.4M+3.9%
Collaboration$53.8M-1.9%
Collaboration services revenues-$4.8M-103%
Discounts and allowances-$248.8M-4.8%

By segment

See full
Reportable Segment$658.7M+10.2%

FAQ

When did Exelixis report Q3 2026 earnings?
Exelixis (EXEL) reported Q3 2026 earnings on October 29, 2026 after market close.
What were Exelixis's Q3 2026 revenue and EPS?
Exelixis reported revenue of $658.7M and eps of $0.94 for Q3 2026.
Did Exelixis beat estimates in Q3 2026?
Revenue beat the consensus estimate of $646.5M by $12.2M. EPS beat the consensus estimate of $0.89 by $0.05.
How did Exelixis's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 10.2% from $597.8M a year earlier and eps grew 20.5% from $0.78.
Where can I find Exelixis's Q3 2026 SEC filings?
You can read the 8-K earnings release (0000939767-26-000114) and the 10-Q periodic report (0000939767-26-000116) directly on SEC EDGAR. The filing index links above go to sec.gov.